Dianthus Therapeutics, Inc. /DE/ (DNTH) Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Dianthus Therapeutics, Inc. NASDAQ:DNTH Healthcare · Biotechnology
Mkt Cap $4.61B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
Dianthus Therapeutics was named to Fortune's 2026 Best Workplaces in BioPharma list, its inaugural appearance, ranking among the top 30 small- and medium-sized U.S. biopharma companies.
The recognition is based on Great Place To Work's analysis of confidential employee surveys, with nearly 36,000 responses from biotech and pharma employees at certified companies.
The release is a workplace-culture announcement with no financial or pipeline impact; CEO Marino Garcia framed it as evidence of the company's growth-phase culture building.
• 19d ago AI analysis › Press Release
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics granted inducement equity awards to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options for an aggregate 106,000 shares with a 10-year term and an $88.32 exercise price, vesting 25% at the first anniversary and monthly over the following 36 months.
This is a routine administrative disclosure approved by the independent Compensation Committee; it signals hiring but has no material financial impact.
• 1mo ago AI analysis › Press Release ⚠ 2
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Dianthus Therapeutics will present one oral and four poster presentations for claseprubart at the AANEM Annual Meeting, September 29 to October 2, 2026 in Orlando.
The oral presentation covers the interim analysis of the pivotal Phase 3 CAPTIVATE trial in CIDP; investigators cited a 75% response rate in the first 40 participants completing unblinded Part A, with consistent functional improvements and a favorable safety profile.
Dianthus also reaffirmed its timeline: Phase 2 MoMeNtum top-line data in multifocal motor neuropathy in December 2026, a CAPTIVATE Part B timing update by year-end 2026, and Phase 3 EMERGE top-line results in gMG in 2H 2028. Claseprubart remains investigational and unapproved in any jurisdiction.
• 1mo ago AI analysis › Press Release
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics granted equity awards on September 1, 2026, to four newly hired non-executive employees as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
The grants are non-qualified stock options to purchase an aggregate of 52,000 shares with a $106.62 exercise price and a 10-year term, approved by the independent Compensation Committee.
The options vest 25% on the first anniversary of vesting commencement and in equal monthly installments over the following 36 months; the disclosure is routine compensation boilerplate with no material financial impact.
• 1mo ago AI analysis › Press Release
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics (DNTH) announced that its CEO Marino Garcia and CFO Ryan Savitz will participate in three investor conferences throughout September 2026.
The management team is scheduled to attend the Wells Fargo 21st Annual Healthcare Conference, Citi's 2026 Biopharma Back to School Conference, and the 2026 Cantor Global Healthcare Conference.
Activities include fireside chats and one-on-one meetings, with webcasts for the Citi and Cantor events available on the company's website.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Dianthus Therapeutics reported Q2 2026 financial results with approximately $1.2 billion in cash providing runway into 2030, alongside a net loss of $50.2 million driven by Phase 3 clinical trial ramp-up.
The company announced positive interim data from its Phase 3 CAPTIVATE trial in CIDP, showing a 75% response rate that exceeded the 50% target, and completed enrollment in its Phase 2 MoMeNtum trial in MMN with 46 patients.
Regulatory efforts yielded success as the FDA agreed to remove ANA screening criteria for claseprubart trials, while Dianthus also unveiled DNTH312, a new first-in-class bifunctional fusion protein aiming for Phase 1 readiness by year-end 2027.
• 2mo ago AI analysis › Press Release
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Dianthus Therapeutics announced DNTH312, a first-in-class bifunctional fusion protein combining claseprubart and TACI to target aC1s and BAFF/APRIL pathways for severe autoimmune diseases.
Preclinical data indicates DNTH312 has a 22-day non-human primate half-life and comparable potency to current therapies, with new IP protection expected to extend at least through 2047.
The company aims to have DNTH312 ready for Phase 1 trials by the end of 2027, expanding its focus in neuromuscular and broader autoimmune conditions.
• 2mo ago AI analysis › Press Release
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Dianthus Therapeutics granted inducement awards to six newly hired non-executive employees as approved by its independent Compensation Committee.
The awards consist of options to purchase an aggregate of 87,000 shares at an exercise price of $106.02 per share with a 10-year term.
Vesting begins with 25% on the first anniversary, followed by equal monthly installments over the subsequent 36 months.
• 2mo ago AI analysis › Press Release
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics granted inducement awards to five newly-hired non-executive employees approved by its independent Compensation Committee.
The awards consist of non-qualified stock options to purchase an aggregate of 58,000 shares of common stock with an exercise price of $90.21 per share.
The options have a 10-year term and vest as to 25% on the first anniversary, with the remainder vesting in equal monthly installments over the following 36 months.
• 4mo ago AI analysis › Press Release ● Major
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Dianthus Therapeutics announced the initiation of the Phase 3 EMERGE trial evaluating Claseprubart in patients with acetylcholine receptor antibody positive generalized Myasthenia Gravis.
The global study will enroll approximately 195 participants to assess subcutaneous dosing every two or four weeks, with top-line results anticipated in the second half of 2028.
Management also provided pipeline guidance, expecting Phase 2 data in Multifocal Motor Neuropathy in Q4 2026 and a timing update for a Phase 3 CIDP trial by year-end 2026.
• 4mo ago AI analysis › Press Release
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics granted 60,000 stock options to three newly hired non-executive employees as material inducements to employment.
The grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and carry an exercise price of $89.45 per share.
Options vest with a 25% cliff after one year, followed by monthly vesting over the subsequent 36 months, under a 10-year term.
• 4mo ago AI analysis › Press Release
Dianthus Therapeutics to Participate in Two Investor Conferences
Dianthus Therapeutics will participate in two major healthcare investor conferences in June 2026.
CFO Ryan Savitz will speak at the Jefferies Global Healthcare Conference on June 3, while CEO Marino Garcia will speak at the Goldman Sachs Global Healthcare Conference on June 9.
Webcasts of these presentations will be available on the company's investor relations website.
• 5mo ago AI analysis › Press Release
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
globenewswire.com • 5mo ago Press Release
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis as the first three indications for its lead asset LBL-047 (DNTH212), a bifunctional fusion protein targeting pDC BDCA2 and inhibiting BAFF/APRIL.
A two-part Phase 1 study in China was initiated in December 2025, with top-line results in healthy volunteers expected in the second half of 2026.
The development of LBL-047 is supported by a strong capital base following a recent $719 million public offering and an exclusive global partnership with Leads Biolabs with a total potential deal value of $1 billion.
• 5mo ago AI analysis › Press Release ● Major ⚠ 1
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics reported a strengthened balance sheet with approximately $1.2 billion in cash as of March 31, 2026, providing runway into 2030 following a $719 million public offering.
The company achieved an early GO decision in the Phase 3 CAPTIVATE trial for CIDP after identifying 20 confirmed responders with fewer than 40 participants completing Part A.
Claseprubart received FDA Orphan Drug Designation for Myasthenia Gravis, and the Phase 3 EMERGE trial remains on track to initiate in mid-2026.
Q1 financial results showed a net loss of $40.8 million, or $0.85 per share, driven by increased R&D spending of $34.5 million.
• 5mo ago AI analysis › Press Release
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 6mo ago Press Release
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 6mo ago Press Release ● Critical
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com • 7mo ago 
